![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Rates and predictors of HBsAg loss after discontinuation of effective long-term entecavir or tenofovir therapy in non-cirrhotic
HBeAg-negative chronic hepatitis B patients:
Results from the prospective DARING-B Greek study.
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
M Papatheodoridi1, E Rigopoulou2, E Hadziyannis3, K Zachou2, V Xourafas1, A Lyberopoulou2, N Gatselis2, J, S Manolakopoulos1,3, GN Dalekos2,
GV Papatheodoridis1.
![0430181](../images%20/043018/043018-4/0430181.gif)
![0430182](../images%20/043018/043018-4/0430182.gif)
![0430183](../images%20/043018/043018-4/0430183.gif)
![0430184](../images%20/043018/043018-4/0430184.gif)
![0430185](../images%20/043018/043018-4/0430185.gif)
![0430186](../images%20/043018/043018-4/0430186.gif)
![0430187](../images%20/043018/043018-4/0430187.gif)
![0430188](../images%20/043018/043018-4/0430188.gif)
![0430189](../images%20/043018/043018-4/0430189.gif)
![04301810](../images%20/043018/043018-4/04301810.gif)
![04301811](../images%20/043018/043018-4/04301811.gif)
![04301812](../images%20/043018/043018-4/04301812.gif)
![04301813](../images%20/043018/043018-4/04301813.gif)
![04301814](../images%20/043018/043018-4/04301814.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|